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Abstract
Objective Well-established cancer registries that routinely
link to death registrations can estimate prevalence directly
by counting patients alive at a particular point in time
(observed prevalence). Such direct methods can only pro-
vide prevalence for the years over which the registry has
been operational. Time-defined estimates, including 5- and
10-year prevalence, may however underestimate the total
cancer burden, and compared with other cancers, there is a
lack of accurate information on the total prevalence of
hematological malignancy subtypes. Accordingly, we
aimed to estimate prevalence (observed and total preva-
lence) of hematological malignancies and precursor con-
ditions by clinically meaningful subtypes using data from
the UK’s specialist population-based register, the Haema-
tological Malignancy Research Network (www.hmrn.org).
Methods Observed and total prevalences were estimated
from 15,810 new diagnoses of hematological malignancies
from 2004 to 2011 and followed up to the 31 August 2011
(index data). Observed prevalence was calculated by the
counting method, and a method based on modelling inci-
dence and survival was used to estimate total prevalence.
Estimates were made according to current disease classi-
fication for the HMRN region and for the UK.
Results The overall observed and total prevalence rates
were 281.9 and 548.8 per 100,000, respectively; the total
number of observed and total prevalent cases in the UK
was estimated as 165,841 and 327,818 cases, as expected
variation existed by disease subtype reflecting the hetero-
geneity in underlying disease incidence, survival and age
distribution of hematological cancers.
Conclusions This study demonstrates the importance of
estimating ‘total’ prevalence rather than ‘observed’
prevalence by current disease classification (ICD-O-3),
particularly for subtypes that have a more indolent nature
and for those that are curable. Importantly, these analyses
demonstrate that relying on observed prevalence alone
would result in a significant underestimation of the relative
burden of some subtypes. While many of these cases may
be considered cured and no longer being actively treated,
people in this survivorship phase may have long-term
medical needs and accordingly, it is important to provide
accurate counts to allow for healthcare planning.
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Introduction
Cancer prevalence may be defined as the proportion of
people in a population who have ever received a cancer
diagnosis in the past and who are alive on a specified
date—the index date. Cancer prevalence, which is gener-
ally estimated using data from cancer registries [1], pro-
vides information on the healthcare needs of cancer
patients who are on long-term medication and/or who are
being monitored at regular intervals. In addition, for can-
cers that can be cured, prevalence is used to estimate the
size of the survivor population.
Well-established cancer registries that routinely link to
death registrations can estimate prevalence directly by
counting patients alive at a particular point in time. Such
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direct methods can, however, only provide prevalence for
the years over which the registry has been operational: the
term observed prevalence often being used to describe
estimates derived from registries that have been established
for shorter periods. In such cases, it is common practice to
quote the length over which the registry has been func-
tioning alongside the observed prevalence estimate. Like-
wise, 5- and 10-year prevalence estimates are commonly
used to assess cancer burden: The former estimating
patients diagnosed and ascertained in the previous 5 years
and the latter in the previous 10 years. Time-defined
prevalence estimates may, however, underestimate the total
cancer burden, and in order to provide better guidance for
healthcare planning, a variety of methods have been
developed to estimate total prevalence (the proportion of
the population alive on the index date who have ever
received a diagnosis of the cancer). Total prevalence is
usually estimated using models that incorporate incidence
and survival [2–7].
Compared with other cancers, there is a lack of accurate
information on the total prevalence of clinically meaning-
ful hematological malignancy subtypes. This is partly
because these complex cancers are diagnosed using a
combination of histology, cytology, immunophenotype,
cytogenetics, imaging and clinical data, and this range and
depth of data are difficult for cancer registries to access
systematically [8, 9]. Hence, the broad ICD-10 classifica-
tion (leukemia, Hodgkin lymphoma, non-Hodgkin lym-
phoma and myeloma) has continued to be applied by many
national registries [10], including the UK’s National Can-
cer Intelligence Network, the USA’s Surveillance, Epi-
demiology and End Results Program and the WHO’s
International Agency for Research on Cancer [11–14].
Accordingly, the present study aims to estimate preva-
lence (observed prevalence and total prevalence) of
hematological malignancies for clinically meaningful
subtypes using data from the UK’s specialist population-
based register, the Haematological Malignancy Research
Fig. 1 Population age and sex structure of the Haematological
Malignancy Research Network (HMRN) region (bars) compared to
the UK as a whole (lines), 2001 [16]
Table 1 Subtypes considered in this study, according to their incidence and survival categoriesa
Incidence (per
100,000)
Survival
Poor (5-year survival
\30 %)
Medium (5-year survival 30–70 %) Good (5-year survival[70 %)
Low (\2) Chronic myelomonocytic
leukemia
Acute lymphoblastic leukemia Chronic myelogenous leukemia
Mantle cell lymphoma T cell leukemia Hairy cell leukemia
Burkitt lymphoma
T cell lymphoma
Plasmacytoma
Lymphoproliferative disorder not otherwise
specified
Medium (2–5) Acute myeloid leukemia Marginal zone lymphoma Follicular lymphoma
Myelodysplastic syndromes Hodgkin lymphoma
Monoclonal B cell lymphocytosis
High ([5) Chronic lymphocytic leukemia Myeloproliferative neoplasms
Diffuse large B cell lymphoma Monoclonal gammopathy of undetermined
significance
Plasma cell myeloma
a Incidence and 5-year survival rates in HMRN from 2004 to 2011. Categories were made for this analysis only and cannot be generalized to
other diseases or other data
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Network (www.hmrn.org) [15]. In addition, because
hematological malignancies can be diagnosed at any age
and survival patterns tend to differ between children and
adults, adaptations to the statistical models used to estimate
total prevalence were developed and applied.
Methods
Data
Data are from the UK’s population-based Haematological
Malignancy Research Network (HMRN). Full details of its
structure, data collection methods and ethical approvals
have been described previously [16]. Briefly, within
HMRN, patient care is provided by 14 hospitals, and as a
matter of policy, all diagnoses are made in a single
department that contains all relevant expertise and tech-
nologies to provide an integrated diagnostic service
including histology, cytology, immunophenotyping and
molecular cytogenetics. All diagnoses are coded to current
WHO classification. Established in September 2004,
HMRN collects information on all patients newly diag-
nosed with hematological malignancies in the study area
(catchment population *4 million, with *2,200 new
diagnoses per year) [15]. HMRN has Section 251 support
under the NHS Act 2006, and all patients have full treat-
ment, response and outcome data collected to clinical trial
standards; all are ‘flagged’ for death registrations at the
national Medical Research Information Service (MRIS).
Calculating prevalence
The index date for prevalence calculations was taken to be
31 August 2011. Observed prevalence was calculated
directly by counting the number of survivors newly diag-
nosed with a hematological cancer from 1 September 2004
to 31 August 2011, alive on the index date (31 August
2011). Total prevalence for each subtype was derived by
applying an estimated correction factor, the completeness
index (R), defined as the proportion of the total prevalence
represented by the observed prevalence as described by
Capocaccia and Angelis [17].
The calculation of the completeness index is based on
incidence and survival models [17]. To accommodate the
characteristics of hematological malignancies, a regression
spline was used to estimate incidence for single ages. This
nonparametric method makes a smoothing curve, which is
not sensitive to the assumptions made for a parametric
incidence function. For survival models, the Weibull
Fig. 2 Age (years) at diagnosis (with red lines indicating median ages), distributions: Haematological Malignancy Research Network
2004–2011. MGUS monoclonal gammopathy of undetermined significance. (Color figure online)
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function has previously been successfully applied to
prevalence estimates [17–19]. Based on the Weibull
function, the influence of age at diagnosis was described
using spline and modelled with an exponential factor of
survival function.
As the age and sex structure in the HMRN region mir-
rors that of the UK as a whole (Fig. 1), national prevalence
was estimated by applying the HMRN rates to the UK
population for both genders. All calculations were con-
ducted using Stata 11.0 and R 3.0.1 software.
Results
There were 15,810 diagnoses of hematological malignan-
cies from 2004 to 2011, of which 8,799 were among males
(55.7 %) and 7,011 were females (44.3 %). The crude
incidence rate for all hematological cancers combined was
63.2 per 100,000 per year and, as expected, incidence and
survival varied by subtype: This variation is summarized in
Table 1, where diagnoses are grouped according to their
incidence magnitude (\2, 2–5,[5 per 100,000) and overall
survival (\30, 30–70,[70 %). In addition to incidence and
survival, age at diagnosis plays an important role in
prevalence, and as with incidence and survival, hemato-
logical malignancies exhibit much greater variation than
most other cancers. Indeed, with different subtypes domi-
nating at different ages, hematological malignancy can be
diagnosed at any age; the median age at diagnosis ranging
from 15.3 years for acute lymphoblastic leukemia to
77.3 years for chronic myelomonocytic leukemia. Most
subtypes had an older median diagnostic age (70.6 years
for all hematological malignancies combined) (Fig. 2).
Observed and total prevalence estimates (per 100,000)
together with completeness indices (R) are presented in
Table 2. The overall observed prevalence rate was 281.9
Table 2 Observed and total prevalence (per 100,000) by sex: Haematological Malignancy Research Network 2004–2011
Total Male Female
R Observed Total R Observed Total R Observed Total
Total 0.51 281.9 548.8 0.54 318 587.7 0.48 248.1 512.3
Leukemia 0.55 60.9 111.3 0.55 76.6 138.8 0.54 46.2 85.5
Chronic myelogenous leukemia 0.39 5.8 14.7 0.42 7.2 17.1 0.36 4.5 12.5
Chronic myelomonocytic leukemia 0.93 1.8 1.9 0.95 2.1 2.2 0.91 1.5 1.7
Acute myeloid leukemia 0.83 7.9 9.6 0.88 9.0 10.2 0.77 6.9 9.0
Acute lymphoblastic leukemia 0.39 5.6 14.5 0.41 6.8 16.5 0.35 4.5 12.6
Chronic lymphocytic leukemia 0.58 35.9 62.1 0.57 46.5 81.3 0.59 25.9 44.1
Hairy cell leukemia 0.41 2.0 4.9 0.39 3.4 8.6 0.54 0.8 1.5
T cell leukemia 0.53 1.9 3.6 0.58 1.7 3.0 0.51 2.1 4.2
Non-Hodgkin lymphoma 0.55 74.7 136.9 0.55 81.3 147.4 0.54 68.4 127.1
Marginal zone lymphoma 0.59 17.1 28.9 0.59 19 32.1 0.59 15.3 26.0
Follicular lymphoma 0.48 18.5 38.5 0.53 17.6 33.4 0.45 19.3 43.3
Mantle cell lymphoma 0.90 2.7 3.0 0.89 3.9 4.3 0.93 1.6 1.8
Diffuse large B cell lymphoma 0.57 31.5 55.1 0.56 34.5 61.2 0.58 28.7 49.4
Burkitt lymphoma 0.29 1.4 4.8 0.26 2.2 8.3 0.41 0.6 1.5
T cell lymphoma 0.54 3.6 6.6 0.53 4.3 8.1 0.56 2.9 5.2
Hodgkin lymphoma 0.24 17.3 72.4 0.27 19.8 73.3 0.21 15.0 71.5
Myeloma 0.79 23.8 30.1 0.78 29.4 37.5 0.80 18.6 23.1
Plasma cell myeloma 0.80 21.3 26.5 0.79 25.7 32.4 0.82 17.2 21.0
Plasmacytoma 0.71 2.5 3.5 0.72 3.7 5.1 0.69 1.4 2.1
Myelodysplastic syndromes 0.95 9.5 10.0 0.95 12.4 13.0 0.94 6.8 7.3
Other neoplasms of uncertain or unknown behavior 0.51 95.7 188.1 0.55 98.5 177.7 0.47 93.0 197.9
Myeloproliferative neoplasms 0.53 35.4 67.2 0.51 32.4 63.0 0.54 38.2 71.2
Monoclonal B cell lymphocytosis 0.50 16.5 32.9 0.58 18.2 31.3 0.43 14.9 34.5
Monoclonal gammopathy of undetermined significance 0.49 35.1 72.0 0.59 37.7 63.9 0.41 32.7 79.5
Lymphoproliferative disorder not otherwise specified 0.54 8.7 16.0 0.52 10.2 19.5 0.57 7.2 12.6
Index date of 31 August 2011
R: completeness index
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per 100,000, compared to a total prevalence rate of 548.8
per 100,000, the completeness index of 0.51 suggesting
that around half of prevalent cases are not captured using
observed prevalence. This varied by diagnostic subtype,
ranging from 0.24 for Hodgkin lymphoma through to 0.90
for mantle cell lymphoma. As expected, subtypes with
longer survival exhibited the largest differences between
observed and total prevalence, whereas for those with poor
survival, the estimates were much closer. For example,
patients diagnosed with chronic myelomonocytic leukemia
or mantle cell lymphoma during the study period had
5-year overall survival estimates\30 % (Table 1), and so
completeness indices were high at 0.93 and 0.90,
respectively. By contrast, patients diagnosed with chronic
myelogenous leukemia or hairy cell leukemia, both of
whom had 5-year overall survival estimates [70 %
(Table 1), had comparatively low completeness estimates
of 0.39 and 0.41, respectively.
In general, the difference between observed and total
prevalence was greater for subtypes with more cases
diagnosed at a young age. For example, although both
Hodgkin lymphoma and follicular lymphoma have a
medium incidence (2–5 per 100,000) and good survival (5-
year survival[70 %) (Table 1), the completeness index of
follicular lymphoma (0.48) was double that of Hodgkin
lymphoma (0.24). This is because younger patients with
0 5,000 10,000 15,000 20,000 25,000
Number of prevalent cases
   Chronic myelomonocytic leukemia
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   Mantle cell lymphoma
   Plasmacytoma
   T-cell lymphoma
   Burkitt lymphoma
   Hairy cell leukemia
   Acute myeloid leukemia
   Myelodysplastic syndroms
   Acute lymphoblastic leukemia
   Chronic myelogenous leukemia
Lymphoproliferative disorder not otherwise specified
   Monoclonal B-cell Lymphocytosis
   Marginal zone lymphoma
   Follicular lymphoma
   Plasma cell myeloma
   Diffuse large B-cell lymphoma
   Myeloproliferative neoplasms
Monoclonal gammopathy of undetermined significance
   Hodgkin Lymphoma
   Chronic lymphocytic leukemia
Observed Total
Fig. 3 Observed and total
prevalence cases for males in
the UK on 31 August 2011.
(Color figure online)
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Fig. 4 Observed and total
prevalence cases for females in
the UK on 31 August 2011.
(Color figure online)
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Hodgkin lymphoma tend to be cured, resulting in a larger
number of prevalent cases after middle age, while follicular
lymphoma is rarely diagnosed before the age of 40 years.
Observed and total prevalence estimates for the UK as a
whole are presented in Figs. 3 (males) and 4 (females):
observed prevalence (blue bars) and total prevalence
(blue ? red bar). Hematological malignancy subtypes are
ranked in order of descending total prevalence. In total, the
observed prevalence was estimated to be 165,841 cases and
total prevalence 327,818 cases. Table 3 lists the UK
observed and total prevalence estimates of the top five most
prevalent hematological malignancies for males and females
separately. Clearly, relying on observed prevalence alone
would have resulted in a significant underestimation of the
relative burden of some diseases. Observed prevalence, for
example, ranks Hodgkin lymphoma as 6th for men and 8th
for women, whereas total prevalence places it second for
both genders. In other words, compared with observed
prevalence, the relative contribution of Hodgkin lymphoma
increases when longer prevalence periods are considered.
Discussion
This study is the first to estimate observed and total
prevalence for hematological malignancies using up-to-
date clinically meaningful disease classifications. The
results suggest that at any one time, around 19,700 people
in the study region are likely to be living with a prior
diagnosis of a hematological malignancy or a recognized
precursor condition (monoclonal gammopathy of uncertain
significance or monoclonal B cell lymphocytosis): In total,
this equates to around 327,800 people in the UK. After
calculating total prevalence, the most prevalent malignancy
in men was chronic lymphocytic leukemia and Hodgkin
lymphoma in women.
Established in 2004, the HMRN’s population-based
patient cohort provided an estimate of hematological
malignancy prevalence that accounted for about half of the
total (completeness index of 0.51). Consistent with
expectations, the differences between total prevalence and
observed prevalence estimates were typically seen in less
fatal cancers that are commonly diagnosed at a younger
age. For example, Hodgkin lymphoma generally has good
survival, and total prevalence estimates exceed those of
observed prevalence, while the difference between
observed prevalence and total prevalence is slight for
mantle cell lymphoma which has generally poor survival.
Again, as expected, large differences between observed
and total prevalence were also seen for precursor condi-
tions. Information on 3-, 5- and 10-year prevalence is
available on the study’s website (www.hmrn.org/statistics/
prevalence) and has been published for the lymphomas and
myeloid malignancies [20, 21].
Not only is the HMRN region similar to the UK as a
whole in terms of its age and sex distribution, but it is also
broadly similar by urban/rural and deprivation status [16];
accordingly, rates were not standardized by age and sex.
Likewise, according to the 2011 [22] census, the proportion
of HMRN’s population classified as white was the same as
the UK as a whole (87 %). However, some ethnic groups
are underrepresented in the region primarily the black
ethnic group. For some hematological malignancies, such
as myeloma, incidence and survival have been shown to
vary by ethnicity with higher rates of both in black ethnic
groups [14, 23, 24]. Accordingly, HMRN rates may
Table 3 Comparison of observed (7-year) and total prevalence of the top five hematological malignancies by gender in the UK
Observed Total
Disease Prevalence Disease Prevalence
Male Male
Chronic lymphocytic leukemia 13,300 Chronic lymphocytic leukemia 23,222
Monoclonal gammopathy of undetermined significance 10,772 Hodgkin lymphoma 20,950
Diffuse large B cell lymphoma 9,847 Monoclonal gammopathy of undetermined significance 18,274
Myeloproliferative neoplasms 9,268 Myeloproliferative neoplasms 18,007
Plasma cell myeloma 7,352 Diffuse large B cell lymphoma 17,483
Female Female
Myeloproliferative neoplasms 11,536 Monoclonal gammopathy of undetermined significance 24,020
Monoclonal gammopathy of undetermined significance 9,878 Hodgkin lymphoma 21,608
Diffuse large B cell lymphoma 8,664 Myeloproliferative neoplasms 21,515
Chronic lymphocytic leukemia 7,827 Diffuse large B cell lymphoma 14,924
Follicular lymphoma 5,825 Chronic lymphocytic leukemia 13,316
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underestimate myeloma prevalence in areas of the country
with a higher proportion of black people [25].
This study assumes that the survival rate was constant
over time; however, for some subtypes, there has been
dramatic changes in outcomes due to the introduction of
new treatments, for example, the introduction of tyrosine
kinase inhibitors has transformed the survival in chronic
myelogenous leukemia (CML) from a fatal disease in non-
transplanted patients to one where patients can now
achieve a near normal life span [26]. While CML is a rare
disease (1 per 100,000), the utilization of current survival
rates may lead to an overestimate in prevalence; accord-
ingly, methods to estimate total prevalence need to be
adapted to account for changes in outcome due to the
introduction of novel therapies.
The major aim of this study was to estimate the preva-
lence of hematological malignancies and precursor condi-
tions for clinically relevant diagnostic groups and explore
the impact of calculating observed and total prevalence by
current disease classification. For some subtypes, calcu-
lating observed prevalence would lead to an underestima-
tion of the prevalent population, as cases diagnosed prior to
the establishment of HMRN will not be captured. While
many of these cases may be considered cured and no longer
being actively treated, people in this survivorship phase
may have long-term medical needs, and accordingly, it is
important to provide accurate counts to allow for health-
care planning.
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